Skip Navigation Links   >   Home   >   News & Media
01 June 2021

OCT Forges Partnership with Voisin Consulting Life Sciences

OCT Forges Partnership with Voisin Consulting Life Sciences

Oxford Cannabinoid Technologies Holdings plc (“OCTP”), the UK-based pharmaceutical company focussed on developing cannabinoid-based prescription medicines approved by regulatory agencies, is delighted today to announce that it has entered into a new partnership with Voisin Consulting Life Sciences (“VCLS”), an international HealthTech and product consultancy which has offices in the UK, Europe, US and India. VCLS has expertise in medical devices, cannabinoids, neurological disorders and addiction, providing services that will:

  • support and develop a regulatory strategy and roadmap for the UK and the US markets as a priority and consider potential subsequent development in the EU;
  • provide a high-level nonclinical gap analysis of OCTP’s development plan to support First Time in Humans (FTiH) clinical trials; and
  • provide a high-level review of OCTP’s clinical development plan in relation to FTiH studies planned in patients;

This exciting partnership will provide significant support for OCTP’s development of its lead drug candidate, OCT461201, in the areas of post-herpetic neuralgia and IBS related visceral pain. OCTP has previously engaged VCLS on regulatory matters relating to the development of its phytocannabinoid drug candidate.

Dr John Lucas, Chief Executive Officer of OCTP, said: we are delighted to continue to partner with Voisin Consulting Life Sciences in our quest to deliver life-changing therapies for severe pain. OCTP, which recently listed on the London Stock Exchange (LSE: OCTP), wants its innovative strategy to have the necessary depth in strength and quality which is crucial to deliver a much-needed product that is both safe and efficacious. Our management team is determined to do the right thing for its patients, and we believe that a consultancy firm like VCLS can provide us with best-in-class support. As a consequence of our early discussions with the VCLS team, it became clear that their expertise, knowledge, and quality meant they were the partners we were looking for.”

Emmanuelle M Voisin, Founder and CEO of Voisin Consulting Life Sciences, said: “we are thrilled to be partnering with Oxford Cannabinoid Technologies at this important stage, to support it on its exciting journey to become the global leader in developing cannabinoid-based prescription medicines. I am delighted that OCTP has chosen Voisin Consulting Life Sciences to facilitate its delivery of innovative, life-changing pain medication.”

 

    All News

    • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

      02 September 2021 US Market
    • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

      06 July 2021 Partnership
    • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      24 June 2021 iCDP Speaker
    • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      22 June 2021 Meet the Team Interview Series
    • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

      04 June 2021 Live Presentation
    • OCT Forges Partnership with Voisin Consulting Life Sciences

      OCT Forges Partnership with Voisin Consulting Life Sciences

      01 June 2021 OCT Partnership
    • Oxford Cannabinoid Technologies Announces Changes to Executive Team

      11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
    • OCT Company Values: How We Pursue Our Mission and Vision

      OCT Company Values: How We Pursue Our Mission and Vision

      01 December 2020 OCT Company Values
    • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

      Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

      26 October 2020 Meet the Team Interview Series
    • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

      07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
    • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

      OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

      28 July 2020 OCT Press Release
    • Cannabinoids in medicine part 5: Treating COVID-19

      17 June 2020 Open Access Government
    • Why the Government should continue to invest in Life Sciences post COVID-19

      Why the government should continue to invest in Life Sciences post COVID-19

      01 June 2020 OCT blog - John Lucas, COO
    • OCT researchers publish new study examining genes involved in treating neuropathic pain

      19 April 2020 OCT Press Release
    • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

      03 April 2020 OCT Press Release
    • Cannabinoids in medicine part 4: Epilepsy

      30 March 2020 Open Access Government
    • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

      07 January 2020 Open Access Government
    • Cannabinoids in medicine Part 2: Pain

      11 October 2019 Open Access Government
    • Cannabinoids in medicine Part 1: Cancer

      22 August 2019 Open Access Government
    • An interview with Neil Mahapatra

      08 January 2019 The Times Magazine
    • High life: the start-up hoping to unlock the secrets of medical cannabis

      09 August 2018 Evening Standard
    • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

      28 June 2018 OCT Press Release
    • Embracing the medical potential of cannabinoids

      01 June 2017 The Medicine Maker
    • Smashing the stigma with science

      01 June 2017 The Medicine Maker
    • Oxford University launches £10m research project into medical marijuana

      16 March 2017 Evening Standard
    • Oxford University to launch study on medical benefits of marijuana

      16 March 2017 The Telegraph
    • Oxford University to launch multimillion-dollar medical marijuana research program

      16 March 2017 CNBC
    • Oxford University launches £10m marijuana research programme

      16 March 2017 BBC
    • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

      15 March 2017 OCT Press Release